Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to -$1000.0.

  • Relay Therapeutics' Capital Expenditures fell 10044.05% to -$1000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $409000.0, marking a year-over-year decrease of 8085.21%. This contributed to the annual value of $2.0 million for FY2024, which is 5109.06% down from last year.
  • According to the latest figures from Q3 2025, Relay Therapeutics' Capital Expenditures is -$1000.0, which was down 10044.05% from $26000.0 recorded in Q2 2025.
  • In the past 5 years, Relay Therapeutics' Capital Expenditures registered a high of $2.8 million during Q1 2022, and its lowest value of -$1000.0 during Q3 2025.
  • Its 5-year average for Capital Expenditures is $1.1 million, with a median of $740500.0 in 2021.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 127500.0% in 2021, then crashed by 10044.05% in 2025.
  • Relay Therapeutics' Capital Expenditures (Quarter) stood at $880000.0 in 2021, then soared by 163.18% to $2.3 million in 2022, then crashed by 94.91% to $118000.0 in 2023, then skyrocketed by 92.37% to $227000.0 in 2024, then plummeted by 100.44% to -$1000.0 in 2025.
  • Its Capital Expenditures was -$1000.0 in Q3 2025, compared to $26000.0 in Q2 2025 and $384000.0 in Q1 2025.